Comparison of second-line therapy in IVIg-refractory Kawasaki disease: a systematic review.

ABSTRACT: BACKGROUND:Evidence remains contradictory regarding second-line therapy in patients with Kawasaki disease (KD) refractory to initial intravenous immunoglobulin (IVIg). The objective of this study aims to evaluate the efficacy and safety of three treatments [i.e. a second IVIg infusion, methylprednisolone (IVMP), and infliximab (IFX)] in patients with refractory KD. METHODS:A systematic search of PubMed, Embase, Cochrane, and ClinicalTrials.gov using predefined MeSH terms was performed from 1990 through 2017. Relevance screening was performed by two independent reviewers. Inclusion criteria included English-only, original clinical data. Eight studies met the inclusion criteria. Fever resolution, coronary lesions, and adverse event outcomes were extracted and pooled for analysis. RESULTS:Of

SUBMITTER: Crayne CB 

PROVIDER: S-EPMC6882052 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature